BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 29904824)

  • 1. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
    Iwamoto J; Okano H; Furuya T; Urano T; Hasegawa M; Hirabayashi H; Kumakubo T; Makita K
    J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
    Tamechika SY; Ohmura SI; Maeda S; Naniwa T
    J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
    Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M; Kohara K; Tabara Y; Ohara M; Takita R; Ochi M; Okada Y; Miki T
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
    Sakai A; Ikeda S; Okimoto N; Matsumoto H; Teshima K; Okazaki Y; Fukuda F; Arita S; Tsurukami H; Nagashima M; Yoshioka T
    Osteoporos Int; 2014 Sep; 25(9):2245-53. PubMed ID: 24899103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
    Inoue Y; Mitsunaga K; Yamamoto T; Chiba K; Yamaide F; Nakano T; Morita Y; Yamaide A; Suzuki S; Arima T; Yamaguchi KI; Tomiita M; Shimojo N; Kohno Y
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):36. PubMed ID: 29914510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
    Tanaka I; Tanaka Y; Soen S; Oshima H
    J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
    J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.
    Tanaka Y; Mori H; Aoki T; Atsumi T; Kawahito Y; Nakayama H; Tohma S; Yamanishi Y; Hasegawa H; Tanimura K; Negoro N; Ueki Y; Kawakami A; Eguchi K; Saito K; Okada Y
    J Bone Miner Metab; 2016 Nov; 34(6):646-654. PubMed ID: 26308708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.